Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Adenocarcinoma
Expression of PRMT5 in lung adenocarcinoma and its significance in epithelial-mesenchymal transition.
Adenocarcinoma in Situ
Expression of PRMT5 in lung adenocarcinoma and its significance in epithelial-mesenchymal transition.
Adenocarcinoma of Lung
An AKT/PRMT5/SREBP1 axis in lung adenocarcinoma regulates de novo lipogenesis and tumor growth.
Adenocarcinoma of Lung
Expression of PRMT5 in lung adenocarcinoma and its significance in epithelial-mesenchymal transition.
Adenocarcinoma of Lung
PRMT5 Selective Inhibitor Enhances Therapeutic Efficacy of Cisplatin in Lung Cancer Cells.
Adenocarcinoma of Lung
Protein arginine methyltransferase 5 is essential for growth of lung cancer cells.
Adenocarcinoma of Lung
Protein arginine methyltransferase 5 mediates enolase-1 cell surface trafficking in human lung adenocarcinoma cells.
Adenoma
High nuclear expression of protein arginine methyltransferase-5 is a potentially useful marker to estimate submucosal invasion in endoscopically resected early colorectal carcinoma.
Alzheimer Disease
The protein arginine methyltransferase PRMT5 regulates A?-induced toxicity in human cells and Caenorhabditis elegans models of Alzheimer's disease.
Arthritis, Rheumatoid
Role of protein arginine methyltransferase 5 in inflammation and migration of fibroblast-like synoviocytes in rheumatoid arthritis.
Astrocytoma
Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro.
Autoimmune Diseases
Protein arginine methyltransferase 5 promotes cholesterol biosynthesis-mediated Th17 responses and autoimmunity.
Bone Resorption
Inhibition of PRMT5 suppresses osteoclast differentiation and partially protects against ovariectomy-induced bone loss through downregulation of CXCL10 and RSAD2.
Brachydactyly
Expanding the clinical and molecular spectrum of PRMT7 mutations: three additional patients and review.
Brachydactyly
Further delineation of the phenotype caused by loss of function mutations in PRMT7.
Brachydactyly
Loss of the arginine methyltranserase PRMT7 causes syndromic intellectual disability with microcephaly and brachydactyly.
Breast Neoplasms
Arginine methylation of SHANK2 by PRMT7 promotes human breast cancer metastasis through activating endosomal FAK signalling.
Breast Neoplasms
Arginine methyltransferase PRMT5 methylates and stabilizes KLF5 via decreasing its phosphorylation and ubiquitination to promote basal-like breast cancer.
Breast Neoplasms
CAPG enhances breast cancer metastasis by competing with PRMT5 to modulate STC-1 transcription.
Breast Neoplasms
Curcumin ameliorates PRMT5-MEP50 arginine methyltransferase expression by decreasing the Sp1 and NF-YA transcription factors in the A549 and MCF-7 cells.
Breast Neoplasms
Elevated expression of protein arginine methyltransferase 5 predicts the poor prognosis of breast cancer.
Breast Neoplasms
Examining Product Specificity in Protein Arginine Methyltransferase 7 (PRMT7) Using Quantum and Molecular Mechanical Simulations.
Breast Neoplasms
Interplay between arginine methylation and ubiquitylation regulates KLF4-mediated genome stability and carcinogenesis.
Breast Neoplasms
Linking PRMT5 to breast cancer stem cells: New therapeutic opportunities?
Breast Neoplasms
LKB1 regulates PRMT5 activity in breast cancer.
Breast Neoplasms
LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity.
Breast Neoplasms
PRMT5 and FOXP1 expression profile in invasive breast cancer patients undergoing neoadjuvant chemotherapy.
Breast Neoplasms
PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer.
Breast Neoplasms
PRMT5 Is a Critical Regulator of Breast Cancer Stem Cell Function via Histone Methylation and FOXP1 Expression.
Breast Neoplasms
PRMT5 Promotes Aerobic Glycolysis and Invasion of Breast Cancer Cells by Regulating the LXR?/NF-?Bp65 Pathway.
Breast Neoplasms
PRMT7 induces epithelial-to-mesenchymal transition and promotes metastasis in breast cancer.
Breast Neoplasms
PRMT7 Methylates Eukaryotic Translation Initiation Factor 2? and Regulates its Role in Stress Granule Formation.
Breast Neoplasms
Proliferative role of TRAF4 in breast cancer by upregulating PRMT5 nuclear expression.
Breast Neoplasms
Protein arginine methyltransferase 5 (PRMT5) activates WNT/?-catenin signalling in breast cancer cells via epigenetic silencing of DKK1 and DKK3.
Breast Neoplasms
Protein arginine methyltransferase 5 accelerates tumor growth by arginine methylation of the tumor suppressor programmed cell death 4.
Breast Neoplasms
Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.
Breast Neoplasms
Protein arginine methyltransferase 7 promotes breast cancer cell invasion through the induction of MMP9 expression.
Breast Neoplasms
Resveratrol modulates epigenetic regulators of promoter histone methylation and acetylation that restores BRCA1, p53, p21CIP1 in human breast cancer cell lines.
Breast Neoplasms
Retraction: Arginine methylation of SHANK2 by PRMT7 promotes human breast cancer metastasis through activating endosomal FAK signalling.
Carcinogenesis
Arginine methyltransferase PRMT5 is essential for sustaining normal adult hematopoiesis.
Carcinogenesis
Cell metabolic profiling of colorectal cancer via 1H NMR.
Carcinogenesis
Development of an AlphaLISA high throughput technique to screen for small molecule inhibitors targeting protein arginine methyltransferases.
Carcinogenesis
Expression of protein arginine methyltransferase-5 in oral squamous cell carcinoma and its significance in epithelial-to-mesenchymal transition.
Carcinogenesis
Identification of a Novel Protein Arginine Methyltransferase 5 Inhibitor in Non-small Cell Lung Cancer by Structure-Based Virtual Screening.
Carcinogenesis
Interplay between arginine methylation and ubiquitylation regulates KLF4-mediated genome stability and carcinogenesis.
Carcinogenesis
Lead induces the up-regulation of the protein arginine methyltransferase 5 possibly by its promoter demethylation.
Carcinogenesis
Methylation of ribosomal protein S10 by protein-arginine methyltransferase 5 regulates ribosome biogenesis.
Carcinogenesis
Methylation of tumor suppressor gene CDH13 and SHP1 promoters and their epigenetic regulation by the UHRF1/PRMT5 complex in endometrial carcinoma.
Carcinogenesis
Myelocytomatosis-Protein Arginine N-Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma.
Carcinogenesis
PRMT5 dimethylates R30 of the p65 subunit to activate NF-?B.
Carcinogenesis
PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis.
Carcinogenesis
PRMT5 Promotes Aerobic Glycolysis and Invasion of Breast Cancer Cells by Regulating the LXR?/NF-?Bp65 Pathway.
Carcinogenesis
PRMT5 promotes cell proliferation by inhibiting BTG2 expression via the ERK signaling pathway in hepatocellular carcinoma.
Carcinogenesis
PRMT5 promotes epithelial-mesenchymal transition via EGFR-?-catenin axis in pancreatic cancer cells.
Carcinogenesis
PRMT5 promotes progression of endometrioid adenocarcinoma via ER? and cell cycle signaling pathways.
Carcinogenesis
PRMT5 Selective Inhibitor Enhances Therapeutic Efficacy of Cisplatin in Lung Cancer Cells.
Carcinogenesis
PRMT5-mediated H4R3sme2 confers cell differentiation in Pediatric B-cell Precursor Acute Lymphoblastic Leukemia.
Carcinogenesis
PRMT7 contributes to the metastasis phenotype in human non-small-cell lung cancer cells possibly through the interaction with HSPA5 and EEF2.
Carcinogenesis
Promotion effect of microcystin-LR on liver tumor progression in krasV12 transgenic zebrafish following acute or subacute exposure.
Carcinogenesis
Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) silencing.
Carcinogenesis
Protein arginine methyltransferase 5 (PRMT5) promotes survival of lymphoma cells via activation of WNT/?-catenin and AKT/GSK3? proliferative signaling.
Carcinogenesis
Protein arginine methyltransferase 5 functions in opposite ways in the cytoplasm and nucleus of prostate cancer cells.
Carcinogenesis
Protein Arginine Methyltransferase 5 Functions via Interacting Proteins.
Carcinogenesis
Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma.
Carcinogenesis
Protein arginine methyltransferase 5 is a key regulator of the MYCN oncoprotein in neuroblastoma cells.
Carcinogenesis
Protein arginine methyltransferase 5 is a potential oncoprotein that upregulates G1 cyclins/cyclin-dependent kinases and the phosphoinositide 3-kinase/AKT signaling cascade.
Carcinogenesis
Protein arginine methyltransferase 5 promotes bladder cancer growth through inhibiting NF-kB dependent apoptosis.
Carcinogenesis
Protein arginine methyltransferase 5 promotes cholesterol biosynthesis-mediated Th17 responses and autoimmunity.
Carcinogenesis
Protein arginine methyltransferase 5 regulates multiple signaling pathways to promote lung cancer cell proliferation.
Carcinogenesis
Proteomics profiling of arginine methylation defines PRMT5 substrate specificity.
Carcinogenesis
Rational Design, synthesis and biological evaluation of novel triazole derivatives as potent and selective PRMT5 inhibitors with antitumor activity.
Carcinogenesis
Role of protein arginine methyltransferase 5 in human cancers.
Carcinogenesis
Selective small-chemical inhibitors of protein arginine methyltransferase 5 with anti-lung cancer activity.
Carcinogenesis
Targeting methyltransferase PRMT5 retards the carcinogenesis and metastasis of HNSCC via epigenetically inhibiting Twist1 transcription.
Carcinogenesis
The methylation induced by protein arginine methyltransferase 5 promotes tumorigenesis and progression of lung cancer.
Carcinogenesis
The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond.
Carcinogenesis
Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma.
Carcinogenesis
Zebrafish prmt5 arginine methyltransferase is essential for germ cell development.
Carcinoma
Arginine methyltransferase PRMT5 methylates and stabilizes KLF5 via decreasing its phosphorylation and ubiquitination to promote basal-like breast cancer.
Carcinoma
Correction: PRMT5 Circular RNA Promotes Metastasis of Urothelial Carcinoma of the Bladder through Sponging miR-30c to Induce Epithelial-Mesenchymal Transition.
Carcinoma
Expression of PRMT5 in lung adenocarcinoma and its significance in epithelial-mesenchymal transition.
Carcinoma
Expression of protein arginine methyltransferase-5 in oral squamous cell carcinoma and its significance in epithelial-to-mesenchymal transition.
Carcinoma
High nuclear expression of protein arginine methyltransferase-5 is a potentially useful marker to estimate submucosal invasion in endoscopically resected early colorectal carcinoma.
Carcinoma
METTL3 Intensifies the Progress of Oral Squamous Cell Carcinoma via Modulating the m6A Amount of PRMT5 and PD-L1.
Carcinoma
Nuclear PRMT5, cyclin D1 and IL-6 are associated with poor outcome in oropharyngeal squamous cell carcinoma patients and is inversely associated with p16-status.
Carcinoma
PRMT5 Circular RNA Promotes Metastasis of Urothelial Carcinoma of the Bladder through Sponging miR-30c to Induce Epithelial-Mesenchymal Transition.
Carcinoma
PRMT5/Wnt4 axis promotes lymph-node metastasis and proliferation of laryngeal carcinoma.
Carcinoma
PRMT7 promotes the growth of renal cell carcinoma through modulating the ?-catenin/C-MYC axis.
Carcinoma
Protein Arginine Methyltransferase 5 Promotes Esophageal Squamous Cell Carcinoma Proliferation and Metastasis via LKB1/AMPK/mTOR Signaling Pathway.
Carcinoma
Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
Carcinoma
Sulforaphane suppresses PRMT5/MEP50 function in epidermal squamous cell carcinoma leading to reduced tumor formation.
Carcinoma
Targeting methyltransferase PRMT5 retards the carcinogenesis and metastasis of HNSCC via epigenetically inhibiting Twist1 transcription.
Carcinoma
The LINC01138 interacts with PRMT5 to promote SREBP1-mediated lipid desaturation and cell growth in clear cell renal cell carcinoma.
Carcinoma, Endometrioid
PRMT5 promotes progression of endometrioid adenocarcinoma via ER? and cell cycle signaling pathways.
Carcinoma, Hepatocellular
Myosin phosphatase and RhoA-activated kinase modulate arginine methylation by the regulation of protein arginine methyltransferase 5 in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
PRMT5 competitively binds to CDK4 to promote G1-S transition upon glucose induction in hepatocellular carcinoma.
Carcinoma, Hepatocellular
PRMT5 promotes cell proliferation by inhibiting BTG2 expression via the ERK signaling pathway in hepatocellular carcinoma.
Carcinoma, Hepatocellular
PRMT9 promotes hepatocellular carcinoma invasion and metastasis via activating PI3K/Akt/GSK-3?/Snail signalling.
Carcinoma, Hepatocellular
Prognostic impact of SET domain-containing protein 8 and protein arginine methyltransferase 5 in patients with hepatocellular carcinoma following curative resection.
Carcinoma, Hepatocellular
Protein arginine methyltransferase 5 is implicated in the aggressiveness of human hepatocellular carcinoma and controls the invasive activity of cancer cells.
Carcinoma, Hepatocellular
S-adenosylmethionine:protein methyltransferases in hepatomas.
Carcinoma, Hepatocellular
Targeting PRMT5 Activity Inhibits the Malignancy of Hepatocellular Carcinoma by Promoting the Transcription of HNF4?.
Carcinoma, Hepatocellular
Targeting protein arginine methyltransferase 5 inhibits human hepatocellular carcinoma growth via the downregulation of beta-catenin.
Carcinoma, Hepatocellular
The protein arginine methyltransferase 5 promotes malignant phenotype of hepatocellular carcinoma cells and is associated with adverse patient outcomes after curative hepatectomy.
Carcinoma, Hepatocellular
The Role of the PRMT5-SND1 Axis in Hepatocellular Carcinoma.
Carcinoma, Non-Small-Cell Lung
Expression of PRMT5 in lung adenocarcinoma and its significance in epithelial-mesenchymal transition.
Carcinoma, Non-Small-Cell Lung
Identification of a Novel Protein Arginine Methyltransferase 5 Inhibitor in Non-small Cell Lung Cancer by Structure-Based Virtual Screening.
Carcinoma, Ovarian Epithelial
Overexpression of PRMT5 Promotes Tumor Cell Growth and Is Associated with Poor Disease Prognosis in Epithelial Ovarian Cancer.
Carcinoma, Renal Cell
PRMT7 promotes the growth of renal cell carcinoma through modulating the ?-catenin/C-MYC axis.
Carcinoma, Renal Cell
The LINC01138 interacts with PRMT5 to promote SREBP1-mediated lipid desaturation and cell growth in clear cell renal cell carcinoma.
Carcinoma, Squamous Cell
Sulforaphane suppresses PRMT5/MEP50 function in epidermal squamous cell carcinoma leading to reduced tumor formation.
Carcinoma, Squamous Cell
Targeting methyltransferase PRMT5 retards the carcinogenesis and metastasis of HNSCC via epigenetically inhibiting Twist1 transcription.
Cardiomegaly
Histone H4R3 symmetric di-methylation by Prmt5 protects against cardiac hypertrophy via regulation of Filip1L/?-catenin.
Cardiomegaly
Inhibition of cardiomyocyte hypertrophy by protein arginine methyltransferase 5.
Cardiomegaly
PRMT5 Prevents Cardiomyocyte Hypertrophy via Symmetric Dimethylating HoxA9 and Repressing HoxA9 Expression.
Cardiomyopathy, Dilated
PRMT5 Prevents Dilated Cardiomyopathy via Suppression of Protein O-GlcNAcylation.
Cardiovascular Diseases
Artificial intelligence and leukocyte epigenomics: Evaluation and prediction of late-onset Alzheimer's disease.
Citrullinemia
PRMT7 Interacts with ASS1 and Citrullinemia Mutations Disrupt the Interaction.
Colitis
Protein Arginine Methyltransferase 5 Inhibition Upregulates Foxp3(+) Regulatory T Cells Frequency and Function during the Ulcerative Colitis.
Colitis, Ulcerative
Protein Arginine Methyltransferase 5 Inhibition Upregulates Foxp3(+) Regulatory T Cells Frequency and Function during the Ulcerative Colitis.
Colonic Neoplasms
Protein arginine methyltransferase 5 is implicated in the aggressiveness of human hepatocellular carcinoma and controls the invasive activity of cancer cells.
Colorectal Neoplasms
A Comprehensive Analysis of Symmetric Arginine Dimethylation in Colorectal Cancer Tissues Using Immunoaffinity Enrichment and Mass Spectrometry.
Colorectal Neoplasms
Adapting AlphaLISA high throughput screen to discover a novel small-molecule inhibitor targeting protein arginine methyltransferase 5 in pancreatic and colorectal cancers.
Colorectal Neoplasms
Arginine methylation controls growth regulation by E2F-1.
Colorectal Neoplasms
Cell metabolic profiling of colorectal cancer via 1H NMR.
Colorectal Neoplasms
Development of an AlphaLISA high throughput technique to screen for small molecule inhibitors targeting protein arginine methyltransferases.
Colorectal Neoplasms
High nuclear expression of protein arginine methyltransferase-5 is a potentially useful marker to estimate submucosal invasion in endoscopically resected early colorectal carcinoma.
Colorectal Neoplasms
NAA40 contributes to colorectal cancer growth by controlling PRMT5 expression.
Colorectal Neoplasms
PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression.
Colorectal Neoplasms
PRMT5 promotes colorectal cancer growth by interaction with MCM7.
Colorectal Neoplasms
PRMT5 regulates colorectal cancer cell growth and EMT via EGFR/Akt/GSK3? signaling cascades.
Colorectal Neoplasms
Protein Arginine Methyltransferase 5 as a Therapeutic Target for KRAS Mutated Colorectal Cancer.
Colorectal Neoplasms
Regulation of a PRMT5/NF-?B Axis by Phosphorylation of PRMT5 at Serine 15 in Colorectal Cancer.
Colorectal Neoplasms
Ribavirin inhibits colorectal cancer growth by downregulating PRMT5 expression and H3R8me2s and H4R3me2s accumulation.
Colorectal Neoplasms
Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3.
Communicable Diseases
Protein Arginine Methyltransferase 5 (PRMT5) as an Anticancer Target and Its Inhibitor Discovery.
Cryptorchidism
Loss of the arginine methyltranserase PRMT7 causes syndromic intellectual disability with microcephaly and brachydactyly.
Deltaretrovirus Infections
PRMT5 Is Required for Bovine Leukemia Virus Infection In Vivo and Regulates BLV Gene Expression, Syncytium Formation, and Glycosylation In Vitro.
Encephalomyelitis
Protein arginine methyltransferase 5 promotes cholesterol biosynthesis-mediated Th17 responses and autoimmunity.
Encephalomyelitis, Autoimmune, Experimental
Protein arginine methyltransferase 5 promotes cholesterol biosynthesis-mediated Th17 responses and autoimmunity.
Endometrial Hyperplasia
PRMT5 promotes progression of endometrioid adenocarcinoma via ER? and cell cycle signaling pathways.
Endometrial Neoplasms
PRMT5 promotes progression of endometrioid adenocarcinoma via ER? and cell cycle signaling pathways.
Endometriosis
Protein arginine methyltransferase 5 mediates THP-1-derived macrophage activation dependent on NF-?B in endometriosis.
Enzootic Bovine Leukosis
PRMT5 Is Required for Bovine Leukemia Virus Infection In Vivo and Regulates BLV Gene Expression, Syncytium Formation, and Glycosylation In Vitro.
Epstein-Barr Virus Infections
Arginine Methyltransferases Are Regulated by Epstein-Barr Virus in B Cells and Are Differentially Expressed in Hodgkin's Lymphoma.
Epstein-Barr Virus Infections
Modulation of Epstein-Barr virus nuclear antigen 2-dependent transcription by protein arginine methyltransferase 5.
Epstein-Barr Virus Infections
Protein Arginine Methyltransferase 5 Functions via Interacting Proteins.
Esophageal Squamous Cell Carcinoma
Protein Arginine Methyltransferase 5 Promotes Esophageal Squamous Cell Carcinoma Proliferation and Metastasis via LKB1/AMPK/mTOR Signaling Pathway.
Fanconi Anemia
Epigenetic regulation of Fanconi anemia genes implicates PRMT5 blockage as a strategy for tumor chemosensitization.
Fatty Liver
Inhibition of protein arginine methyltransferase 5 enhances hepatic mitochondrial biogenesis.
Genetic Diseases, Inborn
Novel PRMT7 mutation in a rare case of dysmorphism and intellectual disability.
Glioblastoma
A PRMT5-RNF168-SMURF2 Axis Controls H2AX Proteostasis.
Glioblastoma
Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro.
Glioblastoma
Genetic Validation of the Protein Arginine Methyltransferase PRMT5 as a Candidate Therapeutic Target in Glioblastoma.
Glioblastoma
Identification of 5-benzylidene-2-phenylthiazolones as potent PRMT5 inhibitors by virtual screening, structural optimization and biological evaluations.
Glioblastoma
Inhibiting protein phosphatase 2A increases the antitumor effect of protein arginine methyltransferase 5 inhibition in models of glioblastoma.
Glioblastoma
Integrin ?v?3 Engagement Regulates Glucose Metabolism and Migration through Focal Adhesion Kinase (FAK) and Protein Arginine Methyltransferase 5 (PRMT5) in Glioblastoma Cells.
Glioblastoma
LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity.
Glioblastoma
Myc and Omomyc functionally associate with the Protein Arginine Methyltransferase 5 (PRMT5) in glioblastoma cells.
Glioblastoma
PRMT5 as a druggable target for glioblastoma therapy.
Glioblastoma
PRMT5 inhibition disrupts splicing and stemness in glioblastoma.
Glioblastoma
The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma.
Glioma
Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro.
Glioma
LncRNA SNHG16 Functions as an Oncogene by Sponging MiR-4518 and Up-Regulating PRMT5 Expression in Glioma.
Glioma
Long noncoding RNA LINC00515 promotes cell proliferation and inhibits apoptosis by sponging miR-16 and activating PRMT5 expression in human glioma.
Glioma
Overexpression of HOXC10 promotes angiogenesis in human glioma via interaction with PRMT5 and upregulation of VEGFA expression.
Glucose Intolerance
Islet-Specific Prmt5 Excision Leads to Reduced Insulin Expression and Glucose Intolerance in Mice.
Graft vs Host Disease
PRMT5 regulates T cell interferon response and is a target for acute graft-versus-host disease.
Head and Neck Neoplasms
Nuclear PRMT5, cyclin D1 and IL-6 are associated with poor outcome in oropharyngeal squamous cell carcinoma patients and is inversely associated with p16-status.
Hearing Loss
Further delineation of the phenotype caused by loss of function mutations in PRMT7.
Heart Diseases
Protein Arginine Methyltransferase 5 (PRMT5) as an Anticancer Target and Its Inhibitor Discovery.
Heart Failure
Inhibition of cardiomyocyte hypertrophy by protein arginine methyltransferase 5.
Heart Failure
PRMT5 Prevents Dilated Cardiomyopathy via Suppression of Protein O-GlcNAcylation.
Hematologic Neoplasms
Identification of Selective, Cell Active Inhibitors of Protein Arginine Methyltransferase 5 through Structure-Based Virtual Screening and Biological Assays.
Hematologic Neoplasms
PRMT5 in gene regulation and hematologic malignancies.
Hematologic Neoplasms
PRMT5 regulates cell pyroptosis by silencing CASP1 in multiple myeloma.
Hematologic Neoplasms
Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma.
Hepatitis B
PRMT5 Restricts Hepatitis B Virus Replication via Epigenetic Repression of cccDNA Transcription and Interference with pgRNA Encapsidation.
Hepatitis B
PRMT5: A novel regulator of Hepatitis B virus replication and an arginine methylase of HBV core.
Hepatitis B
PRMT9 promotes hepatocellular carcinoma invasion and metastasis via activating PI3K/Akt/GSK-3?/Snail signalling.
Hepatitis B
Protein Arginine Methyltransferase 5 Functions via Interacting Proteins.
Hodgkin Disease
Arginine Methyltransferases Are Regulated by Epstein-Barr Virus in B Cells and Are Differentially Expressed in Hodgkin's Lymphoma.
Hypogonadism
Pituitary stalk interruption syndrome is characterized by genetic heterogeneity.
Infections
Arginine methyltransferase PRMT5 negatively regulates cGAS-mediated antiviral immune response.
Infections
Dual regulation of Arabidopsis AGO2 by arginine methylation.
Infections
PRMT5 Restricts Hepatitis B Virus Replication via Epigenetic Repression of cccDNA Transcription and Interference with pgRNA Encapsidation.
Infections
Protein Arginine N-methyltransferases 5 and 7 Promote HIV-1 Production.
Infections
Zebrafish prmt7 negatively regulates antiviral responses by suppressing the retinoic acid-inducible gene-I-like receptor signaling.
Infertility, Female
PRMT5 protects genomic integrity during global DNA demethylation in primordial germ cells and preimplantation embryos.
Infertility, Female
PRMT5>regulates ovarian follicle development by facilitating Wt1 translation.
Infertility, Male
PRMT5 Is Involved in Spermatogonial Stem Cells Maintenance by Regulating Plzf Expression via Modulation of Lysine Histone Modifications.
Intellectual Disability
Expanding the clinical and molecular spectrum of PRMT7 mutations: three additional patients and review.
Intellectual Disability
Further delineation of the phenotype caused by loss of function mutations in PRMT7.
Intellectual Disability
Loss of the arginine methyltranserase PRMT7 causes syndromic intellectual disability with microcephaly and brachydactyly.
Intellectual Disability
Novel PRMT7 mutation in a rare case of dysmorphism and intellectual disability.
Laryngeal Neoplasms
PRMT5/Wnt4 axis promotes lymph-node metastasis and proliferation of laryngeal carcinoma.
Leukemia
Epigenetic control via allosteric regulation of mammalian protein arginine methyltransferases.
Leukemia
Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML.
Leukemia
Identification of a novel selective small-molecule inhibitor of protein arginine methyltransferase 5 (PRMT5) by virtual screening, resynthesis and biological evaluations.
Leukemia
Identification of Selective, Cell Active Inhibitors of Protein Arginine Methyltransferase 5 through Structure-Based Virtual Screening and Biological Assays.
Leukemia
Inhibition of DOT1L and PRMT5 promote synergistic anti-tumor activity in a human MLL leukemia model induced by CRISPR/Cas9.
Leukemia
Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization.
Leukemia
PRMT5 in gene regulation and hematologic malignancies.
Leukemia
Prmt5 is essential for early mouse development and acts in the cytoplasm to maintain ES cell pluripotency.
Leukemia
PRMT5 methylome profiling uncovers a direct link to splicing regulation in acute myeloid leukemia.
Leukemia
PRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying Enzymes.
Leukemia
PRMT5 regulates T cell interferon response and is a target for acute graft-versus-host disease.
Leukemia
PRMT5-mediated H4R3sme2 confers cell differentiation in Pediatric B-cell Precursor Acute Lymphoblastic Leukemia.
Leukemia
PRMT5-mediated histone arginine methylation antagonizes transcriptional repression by polycomb complex PRC2.
Leukemia
Protein arginine methyltransferase 5 suppresses the transcription of the RB family of tumor suppressors in leukemia and lymphoma cells.
Leukemia
Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
Leukemia
The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation.
Leukemia
The Fanconi anemia pathway controls oncogenic response in hematopoietic stem and progenitor cells by regulating PRMT5-mediated p53 arginine methylation.
Leukemia
The PAF complex regulation of Prmt5 facilitates the progression and maintenance of MLL fusion leukemia.
Leukemia
Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation.
Leukemia, Erythroblastic, Acute
CARM1-mediated methylation of protein arginine methyltransferase 5 represses human ?-globin gene expression in erythroleukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Genomic deregulation of PRMT5 supports growth and stress tolerance in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Protein arginine methyltransferase 5 suppresses the transcription of the RB family of tumor suppressors in leukemia and lymphoma cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
Leukemia, Myeloid, Acute
Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML.
Leukemia, Myeloid, Acute
PRMT5 methylome profiling uncovers a direct link to splicing regulation in acute myeloid leukemia.
Leukemia, Myeloid, Acute
PRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying Enzymes.
Leukemia, Myeloid, Acute
The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation.
Leukemia-Lymphoma, Adult T-Cell
PRMT5 Is Upregulated in HTLV-1-Mediated T-Cell Transformation and Selective Inhibition Alters Viral Gene Expression and Infected Cell Survival.
Leukocytosis
PRMT5 Inhibition Modulates E2F1 Methylation and Gene-Regulatory Networks Leading to Therapeutic Efficacy in JAK2V617F-Mutant MPN.
Lipodystrophy
Protein Arginine Methyltransferase PRMT5 Regulates Fatty Acid Metabolism and Lipid Droplet Biogenesis in White Adipose Tissues.
Lipodystrophy, Congenital Generalized
Protein Arginine Methyltransferase PRMT5 Regulates Fatty Acid Metabolism and Lipid Droplet Biogenesis in White Adipose Tissues.
Lung Neoplasms
Circular RNA PRMT5 confers cisplatin-resistance via miR-4458/REV3L axis in non-small-cell lung cancer.
Lung Neoplasms
GLI pathogenesis-related 1 functions as a tumor-suppressor in lung cancer.
Lung Neoplasms
Identification of a Novel Protein Arginine Methyltransferase 5 Inhibitor in Non-small Cell Lung Cancer by Structure-Based Virtual Screening.
Lung Neoplasms
PRMT1 loss sensitizes cells to PRMT5 inhibition.
Lung Neoplasms
PRMT5 Enables Robust STAT3 Activation via Arginine Symmetric Dimethylation of SMAD7.
Lung Neoplasms
PRMT5 Promotes EMT Through Regulating Akt Activity in Human Lung Cancer.
Lung Neoplasms
PRMT5 Promotes Human Lung Cancer Cell Apoptosis via Akt/Gsk3? Signaling Induced by Resveratrol.
Lung Neoplasms
PRMT5 promotes inflammation of cigarette smoke extract-induced bronchial epithelial cells by up-regulation of CXCL10.
Lung Neoplasms
PRMT5 Selective Inhibitor Enhances Therapeutic Efficacy of Cisplatin in Lung Cancer Cells.
Lung Neoplasms
PRMT7 contributes to the metastasis phenotype in human non-small-cell lung cancer cells possibly through the interaction with HSPA5 and EEF2.
Lung Neoplasms
Protein arginine methyltransferase 5 is a potential oncoprotein that upregulates G1 cyclins/cyclin-dependent kinases and the phosphoinositide 3-kinase/AKT signaling cascade.
Lung Neoplasms
Protein arginine methyltransferase 5 is essential for growth of lung cancer cells.
Lung Neoplasms
Protein arginine methyltransferase 5 promotes lung cancer metastasis via the epigenetic regulation of miR-99 family/FGFR3 signaling.
Lung Neoplasms
Protein arginine methyltransferase 5 regulates multiple signaling pathways to promote lung cancer cell proliferation.
Lung Neoplasms
Targeting PRMT5/Akt signalling axis prevents human lung cancer cell growth.
Lung Neoplasms
The arginine methyltransferase PRMT5 and PRMT1 distinctly regulate the degradation of anti-apoptotic protein CFLARL in human lung cancer cells.
Lung Neoplasms
The methylation induced by protein arginine methyltransferase 5 promotes tumorigenesis and progression of lung cancer.
Lymphatic Metastasis
PRMT5/Wnt4 axis promotes lymph-node metastasis and proliferation of laryngeal carcinoma.
Lymphatic Metastasis
Protein arginine methyltransferase 5 is associated with malignant phenotype and peritoneal metastasis in gastric cancer.
Lymphatic Metastasis
Protein arginine methyltransferase 5 promotes lung cancer metastasis via the epigenetic regulation of miR-99 family/FGFR3 signaling.
Lymphatic Metastasis
Protein arginine methyltransferase 7 promotes breast cancer cell invasion through the induction of MMP9 expression.
Lymphatic Metastasis
Targeting methyltransferase PRMT5 retards the carcinogenesis and metastasis of HNSCC via epigenetically inhibiting Twist1 transcription.
Lymphoma
Epigenetic control via allosteric regulation of mammalian protein arginine methyltransferases.
Lymphoma
Histone Arginine Methylation by PRMT7 Controls Germinal Center Formation via Regulating Bcl6 Transcription.
Lymphoma
Identification of 5-benzylidene-2-phenylthiazolones as potent PRMT5 inhibitors by virtual screening, structural optimization and biological evaluations.
Lymphoma
Identification of Selective, Cell Active Inhibitors of Protein Arginine Methyltransferase 5 through Structure-Based Virtual Screening and Biological Assays.
Lymphoma
LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity.
Lymphoma
Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma.
Lymphoma
Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase.
Lymphoma
Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization.
Lymphoma
PRMT5 in gene regulation and hematologic malignancies.
Lymphoma
PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival.
Lymphoma
PRMT5 is essential for B cell development and germinal center dynamics.
Lymphoma
PRMT5 Is Required for Bovine Leukemia Virus Infection In Vivo and Regulates BLV Gene Expression, Syncytium Formation, and Glycosylation In Vitro.
Lymphoma
PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells.
Lymphoma
PRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying Enzymes.
Lymphoma
Protein Arginine Methyltransferase 5 (PRMT5) as an Anticancer Target and Its Inhibitor Discovery.
Lymphoma
Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) silencing.
Lymphoma
Protein arginine methyltransferase 5 (PRMT5) promotes survival of lymphoma cells via activation of WNT/?-catenin and AKT/GSK3? proliferative signaling.
Lymphoma
Protein arginine methyltransferase 5 represses tumor suppressor miRNAs that down-regulate CYCLIN D1 and c-MYC expression in aggressive B-cell lymphoma.
Lymphoma
Protein arginine methyltransferase 5 suppresses the transcription of the RB family of tumor suppressors in leukemia and lymphoma cells.
Lymphoma
Rational Design, synthesis and biological evaluation of novel triazole derivatives as potent and selective PRMT5 inhibitors with antitumor activity.
Lymphoma
Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation.
Lymphoma
Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma.
Lymphoma, B-Cell
PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival.
Lymphoma, B-Cell
PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells.
Lymphoma, B-Cell
Protein arginine methyltransferase 5 represses tumor suppressor miRNAs that down-regulate CYCLIN D1 and c-MYC expression in aggressive B-cell lymphoma.
Lymphoma, B-Cell
Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation.
Lymphoma, Large B-Cell, Diffuse
PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells.
Lymphoma, Mantle-Cell
Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma.
Lymphoma, Mantle-Cell
Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization.
Lymphoma, Mantle-Cell
Protein Arginine Methyltransferase 5 (PRMT5) as an Anticancer Target and Its Inhibitor Discovery.
Lymphoma, Mantle-Cell
Rational Design, synthesis and biological evaluation of novel triazole derivatives as potent and selective PRMT5 inhibitors with antitumor activity.
Lymphoma, Non-Hodgkin
Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) silencing.
Lymphoma, Non-Hodgkin
Protein arginine methyltransferase 5 (PRMT5) promotes survival of lymphoma cells via activation of WNT/?-catenin and AKT/GSK3? proliferative signaling.
Lymphoma, Non-Hodgkin
Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma.
Medulloblastoma
Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma.
Melanoma
BRAF inhibition in melanoma is associated with the dysregulation of histone methylation and histone methyltransferases.
Melanoma
Expression of proteins involved in epigenetic regulation in human cutaneous melanoma and peritumoral skin.
Melanoma
Hypoxia-Induced Adaptations of miRNomes and Proteomes in Melanoma Cells and Their Secreted Extracellular Vesicles.
Melanoma
PRMT5 control of cGAS/STING and NLRC5 pathways defines melanoma response to antitumor immunity.
Melanoma
PRMT5 Is Upregulated in Malignant and Metastatic Melanoma and Regulates Expression of MITF and p27(Kip1.)
Melanoma
Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
Melanoma
Shank-associated RH domain interactor signaling in tumorigenesis.
Melanoma
SHARPIN-mediated regulation of protein arginine methyltransferase 5 controls melanoma growth.
Mesothelioma
PRMT5 silencing selectively affects MTAP-deleted mesothelioma: In vitro evidence of a novel promising approach.
Mesothelioma
Sulforaphane inhibits PRMT5 and MEP50 function to suppress the mesothelioma cancer cell phenotype.
Mesothelioma
Transcriptional perturbation of protein arginine methyltransferase-5 exhibits MTAP-selective oncosuppression.
Mesothelioma, Malignant
Transcriptional perturbation of protein arginine methyltransferase-5 exhibits MTAP-selective oncosuppression.
Metabolic Diseases
Inhibition of protein arginine methyltransferase 5 enhances hepatic mitochondrial biogenesis.
Microcephaly
Loss of the arginine methyltranserase PRMT7 causes syndromic intellectual disability with microcephaly and brachydactyly.
Multiple Myeloma
PRMT5 regulates cell pyroptosis by silencing CASP1 in multiple myeloma.
Multiple Myeloma
Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma.
Muscle Hypotonia
PRMT7 as a unique member of the protein arginine methyltransferase family: A review.
Muscular Atrophy, Spinal
SMN and symmetric arginine dimethylation of RNA polymerase II C-terminal domain control termination.
Myocardial Infarction
Low expression of PRMT5 in peripheral blood may serve as a potential independent risk factor in assessments of the risk of stable CAD and AMI.
Neoplasm Metastasis
A TGF?-PRMT5-MEP50 axis regulates cancer cell invasion through histone H3 and H4 arginine methylation coupled transcriptional activation and repression.
Neoplasm Metastasis
Arginine methylation of SHANK2 by PRMT7 promotes human breast cancer metastasis through activating endosomal FAK signalling.
Neoplasm Metastasis
CAPG enhances breast cancer metastasis by competing with PRMT5 to modulate STC-1 transcription.
Neoplasm Metastasis
Correction: PRMT5 Circular RNA Promotes Metastasis of Urothelial Carcinoma of the Bladder through Sponging miR-30c to Induce Epithelial-Mesenchymal Transition.
Neoplasm Metastasis
Gene expression meta-analysis identifies chromosomal regions and candidate genes involved in breast cancer metastasis.
Neoplasm Metastasis
Metadherin-PRMT5 complex enhances the metastasis of hepatocellular carcinoma through the WNT-?-catenin signaling pathway.
Neoplasm Metastasis
METTL3 Intensifies the Progress of Oral Squamous Cell Carcinoma via Modulating the m6A Amount of PRMT5 and PD-L1.
Neoplasm Metastasis
MiR-1266 suppresses the growth and metastasis of prostate cancer via targeting PRMT5.
Neoplasm Metastasis
PRMT5 Circular RNA Promotes Metastasis of Urothelial Carcinoma of the Bladder through Sponging miR-30c to Induce Epithelial-Mesenchymal Transition.
Neoplasm Metastasis
PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PD-L1 expression.
Neoplasm Metastasis
PRMT5/Wnt4 axis promotes lymph-node metastasis and proliferation of laryngeal carcinoma.
Neoplasm Metastasis
PRMT7 as a unique member of the protein arginine methyltransferase family: A review.
Neoplasm Metastasis
PRMT7 contributes to the metastasis phenotype in human non-small-cell lung cancer cells possibly through the interaction with HSPA5 and EEF2.
Neoplasm Metastasis
PRMT7 induces epithelial-to-mesenchymal transition and promotes metastasis in breast cancer.
Neoplasm Metastasis
PRMT7 Interacts with ASS1 and Citrullinemia Mutations Disrupt the Interaction.
Neoplasm Metastasis
PRMT9 promotes hepatocellular carcinoma invasion and metastasis via activating PI3K/Akt/GSK-3?/Snail signalling.
Neoplasm Metastasis
Protein arginine methyltransferase 5 is associated with malignant phenotype and peritoneal metastasis in gastric cancer.
Neoplasm Metastasis
Protein Arginine Methyltransferase 5 Promotes Esophageal Squamous Cell Carcinoma Proliferation and Metastasis via LKB1/AMPK/mTOR Signaling Pathway.
Neoplasm Metastasis
Protein arginine methyltransferase 5 promotes lung cancer metastasis via the epigenetic regulation of miR-99 family/FGFR3 signaling.
Neoplasm Metastasis
Protein arginine methyltransferase 5-mediated epigenetic silencing of IRX1 contributes to tumorigenicity and metastasis of gastric cancer.
Neoplasm Metastasis
Protein arginine methyltransferase 7 promotes breast cancer cell invasion through the induction of MMP9 expression.
Neoplasm Metastasis
Retraction: Arginine methylation of SHANK2 by PRMT7 promotes human breast cancer metastasis through activating endosomal FAK signalling.
Neoplasm Metastasis
Snail/PRMT5/NuRD complex contributes to DNA hypermethylation in cervical cancer by TET1 inhibition.
Neoplasm Metastasis
Targeting methyltransferase PRMT5 retards the carcinogenesis and metastasis of HNSCC via epigenetically inhibiting Twist1 transcription.
Neoplasm Metastasis
The methylation induced by protein arginine methyltransferase 5 promotes tumorigenesis and progression of lung cancer.
Neoplasm, Residual
Overexpression of PRMT5 Promotes Tumor Cell Growth and Is Associated with Poor Disease Prognosis in Epithelial Ovarian Cancer.
Neoplasms
A Comprehensive Analysis of Symmetric Arginine Dimethylation in Colorectal Cancer Tissues Using Immunoaffinity Enrichment and Mass Spectrometry.
Neoplasms
A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models.
Neoplasms
Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing.
Neoplasms
Adapting AlphaLISA high throughput screen to discover a novel small-molecule inhibitor targeting protein arginine methyltransferase 5 in pancreatic and colorectal cancers.
Neoplasms
Aflatoxin-induced upregulation of protein arginine methyltransferase 5 is mediated by protein kinase C and extracellular signal-regulated kinase.
Neoplasms
Allosteric Modulation of Protein Arginine Methyltransferase 5 (PRMT5).
Neoplasms
An AKT/PRMT5/SREBP1 axis in lung adenocarcinoma regulates de novo lipogenesis and tumor growth.
Neoplasms
Anguilla japonica lectin 1 delivery through adenovirus vector induces apoptotic cancer cell death through interaction with PRMT5.
Neoplasms
Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss.
Neoplasms
Arginine Methylation of SREBP1a via PRMT5 Promotes De Novo Lipogenesis and Tumor Growth.
Neoplasms
Arginine methyltransferase inhibitor 1 exhibits antitumor effects against cervical cancer in vitro and in vivo.
Neoplasms
AS1411 Alters the Localization of a Complex Containing Protein Arginine Methyltransferase 5 and Nucleolin.
Neoplasms
CDK6 Antagonizes p53-Induced Responses during Tumorigenesis.
Neoplasms
Cell metabolic profiling of colorectal cancer via 1H NMR.
Neoplasms
Coordinated Splicing of Regulatory Detained Introns within Oncogenic Transcripts Creates an Exploitable Vulnerability in Malignant Glioma.
Neoplasms
Coronin 2A (CRN5) expression is associated with colorectal adenoma-adenocarcinoma sequence and oncogenic signalling.
Neoplasms
Development of an AlphaLISA high throughput technique to screen for small molecule inhibitors targeting protein arginine methyltransferases.
Neoplasms
Discovery and optimization of selective inhibitors of protein arginine methyltransferase 5 by docking-based virtual screening.
Neoplasms
Discovery of a Dual PRMT5-PRMT7 Inhibitor.
Neoplasms
Discovery of a First-in-Class Inhibitor of the PRMT5-Substrate Adaptor Interaction.
Neoplasms
Discovery of First-in-Class Protein Arginine Methyltransferase 5 (PRMT5) Degraders.
Neoplasms
Discovery of new potent protein arginine methyltransferase 5 (PRMT5) inhibitors by assembly of key pharmacophores from known inhibitors.
Neoplasms
Discovery of selective protein arginine methyltransferase 5 inhibitors and biological evaluations.
Neoplasms
Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5.
Neoplasms
Elevated expression of protein arginine methyltransferase 5 predicts the poor prognosis of breast cancer.
Neoplasms
Enhanced arginine methylation of programmed cell death 4 protein during nutrient deprivation promotes tumor cell viability.
Neoplasms
Epigallocatechin gallate inhibits HeLa cells by modulation of epigenetics and signaling pathways.
Neoplasms
Epigenetic regulation of Fanconi anemia genes implicates PRMT5 blockage as a strategy for tumor chemosensitization.
Neoplasms
EPZ015666, a selective protein arginine methyltransferase 5 (PRMT5) inhibitor with an antitumour effect in retinoblastoma.
Neoplasms
Esophageal Squamous Cell Carcinoma Is Accompanied by Local and Systemic Changes in L-arginine/NO Pathway.
Neoplasms
Exploiting the Hidden Treasure of Detained Introns.
Neoplasms
Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro.
Neoplasms
Expression of PRMT5 in lung adenocarcinoma and its significance in epithelial-mesenchymal transition.
Neoplasms
Expression of protein arginine methyltransferase-5 in oral squamous cell carcinoma and its significance in epithelial-to-mesenchymal transition.
Neoplasms
Genetic Validation of the Protein Arginine Methyltransferase PRMT5 as a Candidate Therapeutic Target in Glioblastoma.
Neoplasms
GLI pathogenesis-related 1 functions as a tumor-suppressor in lung cancer.
Neoplasms
High PRMT5 expression is associated with poor overall survival and tumor progression in bladder cancer.
Neoplasms
HiJAKing the methylosome in myeloproliferative disorders.
Neoplasms
HOXA9 Methylation by PRMT5 Is Essential for Endothelial Cell Expression of Leukocyte Adhesion Molecules.
Neoplasms
Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes.
Neoplasms
Hypoxia-Induced Adaptations of miRNomes and Proteomes in Melanoma Cells and Their Secreted Extracellular Vesicles.
Neoplasms
Identification of protein arginine N-methyltransferase 5 (PRMT5) as a novel interacting protein with the tumor suppressor protein RASSF1A.
Neoplasms
Inhibiting protein phosphatase 2A increases the antitumor effect of protein arginine methyltransferase 5 inhibition in models of glioblastoma.
Neoplasms
Inhibition of PRMT5 suppresses osteoclast differentiation and partially protects against ovariectomy-induced bone loss through downregulation of CXCL10 and RSAD2.
Neoplasms
L-Arginine/Nitric Oxide Pathway Is Altered in Colorectal Cancer and Can Be Modulated by Novel Derivatives from Oxicam Class of Non-Steroidal Anti-Inflammatory Drugs.
Neoplasms
Late Cornified Envelope Group I, a novel target of p53, regulates PRMT5 activity.
Neoplasms
Linking PRMT5 to breast cancer stem cells: New therapeutic opportunities?
Neoplasms
LKB1 regulates PRMT5 activity in breast cancer.
Neoplasms
LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity.
Neoplasms
Long noncoding RNA FOXD2-AS1 enhances chemotherapeutic resistance of laryngeal squamous cell carcinoma via STAT3 activation.
Neoplasms
Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma.
Neoplasms
M-TAP Dance: Targeting PRMT1 and PRMT5 Family Members to Push Cancer Cells Over the Edge.
Neoplasms
MEP50/PRMT5-mediated methylation activates GLI1 in Hedgehog signalling through inhibition of ubiquitination by the ITCH/NUMB complex.
Neoplasms
Methylosome protein 50 promotes androgen- and estrogen-independent tumorigenesis.
Neoplasms
Molecular basis for substrate recruitment to the PRMT5 methylosome.
Neoplasms
MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells.
Neoplasms
MTAP Deletion Promotes Cancer-Cell Dependence on PRMT5.
Neoplasms
MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis.
Neoplasms
Myelocytomatosis-Protein Arginine N-Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma.
Neoplasms
NAA40 contributes to colorectal cancer growth by controlling PRMT5 expression.
Neoplasms
Novel PRMT5-mediated arginine methylations of HSP90A are essential for maintenance of HSP90A function in NDRG2low ATL and various cancer cells.
Neoplasms
Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase.
Neoplasms
Nuclear PRMT5, cyclin D1 and IL-6 are associated with poor outcome in oropharyngeal squamous cell carcinoma patients and is inversely associated with p16-status.
Neoplasms
Nucleoside protein arginine methyltransferase 5 (PRMT5) inhibitors.
Neoplasms
Overexpression of PRMT5 Promotes Tumor Cell Growth and Is Associated with Poor Disease Prognosis in Epithelial Ovarian Cancer.
Neoplasms
Pan-methylarginine antibody generation using PEG linked GAR motifs as antigens.
Neoplasms
Pancreatic cancer organoids recapitulate disease and allow personalized drug screening.
Neoplasms
Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization.
Neoplasms
Prenatal and postnatal presentation of PRMT7 related syndrome: Expanding the phenotypic manifestations.
Neoplasms
PRMT1 loss sensitizes cells to PRMT5 inhibition.
Neoplasms
PRMT5 and FOXP1 expression profile in invasive breast cancer patients undergoing neoadjuvant chemotherapy.
Neoplasms
PRMT5 and Tip60 Modify FOXP3 Function in Tumor Immunity.
Neoplasms
PRMT5 Associates With the FOXP3 Homomer and When Disabled Enhances Targeted p185erbB2/neu Tumor Immunotherapy.
Neoplasms
PRMT5 competitively binds to CDK4 to promote G1-S transition upon glucose induction in hepatocellular carcinoma.
Neoplasms
PRMT5 control of cGAS/STING and NLRC5 pathways defines melanoma response to antitumor immunity.
Neoplasms
PRMT5 Cooperates with pICln to Function as a Master Epigenetic Activator of DNA Double-Strand Break Repair Genes.
Neoplasms
PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer.
Neoplasms
PRMT5 dimethylates R30 of the p65 subunit to activate NF-?B.
Neoplasms
PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PD-L1 expression.
Neoplasms
PRMT5 Enables Robust STAT3 Activation via Arginine Symmetric Dimethylation of SMAD7.
Neoplasms
PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis.
Neoplasms
PRMT5 function and targeting in cancer.
Neoplasms
PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression.
Neoplasms
PRMT5 in gene regulation and hematologic malignancies.
Neoplasms
PRMT5 Inhibition Modulates E2F1 Methylation and Gene-Regulatory Networks Leading to Therapeutic Efficacy in JAK2V617F-Mutant MPN.
Neoplasms
PRMT5 Is a Critical Regulator of Breast Cancer Stem Cell Function via Histone Methylation and FOXP1 Expression.
Neoplasms
PRMT5 is required for cell-cycle progression and p53 tumor suppressor function.
Neoplasms
PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells.
Neoplasms
PRMT5 Is Upregulated in Malignant and Metastatic Melanoma and Regulates Expression of MITF and p27(Kip1.)
Neoplasms
PRMT5 methylome profiling uncovers a direct link to splicing regulation in acute myeloid leukemia.
Neoplasms
PRMT5 Modulates Splicing for Genome Integrity and Preserves Proteostasis of Hematopoietic Stem Cells.
Neoplasms
PRMT5 prognostic value in cancer.
Neoplasms
PRMT5 Promotes Aerobic Glycolysis and Invasion of Breast Cancer Cells by Regulating the LXR?/NF-?Bp65 Pathway.
Neoplasms
PRMT5 promotes cancer cell migration and invasion through the E2F pathway.
Neoplasms
PRMT5 promotes cell proliferation by inhibiting BTG2 expression via the ERK signaling pathway in hepatocellular carcinoma.
Neoplasms
PRMT5 promotes colorectal cancer growth by interaction with MCM7.
Neoplasms
PRMT5 Promotes EMT Through Regulating Akt Activity in Human Lung Cancer.
Neoplasms
PRMT5 promotes epithelial-mesenchymal transition via EGFR-?-catenin axis in pancreatic cancer cells.
Neoplasms
PRMT5 Promotes Human Lung Cancer Cell Apoptosis via Akt/Gsk3? Signaling Induced by Resveratrol.
Neoplasms
PRMT5 promotes progression of endometrioid adenocarcinoma via ER? and cell cycle signaling pathways.
Neoplasms
PRMT5 regulates cell pyroptosis by silencing CASP1 in multiple myeloma.
Neoplasms
PRMT5 regulates colorectal cancer cell growth and EMT via EGFR/Akt/GSK3? signaling cascades.
Neoplasms
PRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying Enzymes.
Neoplasms
PRMT5 silencing selectively affects MTAP-deleted mesothelioma: In vitro evidence of a novel promising approach.
Neoplasms
PRMT5, a novel TRAIL receptor-binding protein, inhibits TRAIL-induced apoptosis via nuclear factor-kappaB activation.
Neoplasms
PRMT5-dependent p53 escape in tumorigenesis.
Neoplasms
PRMT5-mediated methylation of YBX1 regulates NF-?B activity in colorectal cancer.
Neoplasms
PRMT5-PTEN molecular pathway regulates senescence and self-renewal of primary glioblastoma neurosphere cells.
Neoplasms
PRMT5-Selective Inhibitors Suppress Inflammatory T Cell Responses and Experimental Autoimmune Encephalomyelitis.
Neoplasms
PRMT5-TRIM21 interaction regulates the senescence of osteosarcoma cells by targeting the TXNIP/p21 axis.
Neoplasms
PRMT5/Wnt4 axis promotes lymph-node metastasis and proliferation of laryngeal carcinoma.
Neoplasms
PRMT5: a putative oncogene and therapeutic target in prostate cancer.
Neoplasms
PRMT7 as a unique member of the protein arginine methyltransferase family: A review.
Neoplasms
PRMT7 induces epithelial-to-mesenchymal transition and promotes metastasis in breast cancer.
Neoplasms
PRMT7 Interacts with ASS1 and Citrullinemia Mutations Disrupt the Interaction.
Neoplasms
PRMT7 promotes the growth of renal cell carcinoma through modulating the ?-catenin/C-MYC axis.
Neoplasms
PRMT9 promotes hepatocellular carcinoma invasion and metastasis via activating PI3K/Akt/GSK-3?/Snail signalling.
Neoplasms
Profiling PRMT methylome reveals roles of hnRNPA1 arginine methylation in RNA splicing and cell growth.
Neoplasms
Prognostic impact of SET domain-containing protein 8 and protein arginine methyltransferase 5 in patients with hepatocellular carcinoma following curative resection.
Neoplasms
Proliferative role of TRAF4 in breast cancer by upregulating PRMT5 nuclear expression.
Neoplasms
Promotion effect of microcystin-LR on liver tumor progression in krasV12 transgenic zebrafish following acute or subacute exposure.
Neoplasms
Protein arginine methyltransferase 5 (PRMT5) activates WNT/?-catenin signalling in breast cancer cells via epigenetic silencing of DKK1 and DKK3.
Neoplasms
Protein Arginine Methyltransferase 5 (PRMT5) and the ERK1/2 & PI3K Pathways: A Case for PRMT5 Inhibition and Combination Therapies in Cancer.
Neoplasms
Protein Arginine Methyltransferase 5 (PRMT5) as an Anticancer Target and Its Inhibitor Discovery.
Neoplasms
Protein arginine methyltransferase 5 (PRMT5) dysregulation in cancer.
Neoplasms
Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) silencing.
Neoplasms
Protein arginine methyltransferase 5 (PRMT5) promotes survival of lymphoma cells via activation of WNT/?-catenin and AKT/GSK3? proliferative signaling.
Neoplasms
Protein arginine methyltransferase 5 accelerates tumor growth by arginine methylation of the tumor suppressor programmed cell death 4.
Neoplasms
Protein Arginine Methyltransferase 5 as a Therapeutic Target for KRAS Mutated Colorectal Cancer.
Neoplasms
Protein arginine methyltransferase 5 catalyzes substrate dimethylation in a distributive fashion.
Neoplasms
Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth.
Neoplasms
Protein arginine methyltransferase 5 functions in opposite ways in the cytoplasm and nucleus of prostate cancer cells.
Neoplasms
Protein Arginine Methyltransferase 5 Functions via Interacting Proteins.
Neoplasms
Protein arginine methyltransferase 5 is a key regulator of the MYCN oncoprotein in neuroblastoma cells.
Neoplasms
Protein arginine methyltransferase 5 is a potential oncoprotein that upregulates G1 cyclins/cyclin-dependent kinases and the phosphoinositide 3-kinase/AKT signaling cascade.
Neoplasms
Protein arginine methyltransferase 5 is an essential component of the hypoxia-inducible factor 1 signaling pathway.
Neoplasms
Protein arginine methyltransferase 5 is associated with malignant phenotype and peritoneal metastasis in gastric cancer.
Neoplasms
Protein arginine methyltransferase 5 is implicated in the aggressiveness of human hepatocellular carcinoma and controls the invasive activity of cancer cells.
Neoplasms
Protein arginine methyltransferase 5 promotes bladder cancer growth through inhibiting NF-kB dependent apoptosis.
Neoplasms
Protein Arginine Methyltransferase 5 Promotes Esophageal Squamous Cell Carcinoma Proliferation and Metastasis via LKB1/AMPK/mTOR Signaling Pathway.
Neoplasms
Protein arginine methyltransferase 5 promotes lung cancer metastasis via the epigenetic regulation of miR-99 family/FGFR3 signaling.
Neoplasms
Protein arginine methyltransferase 5 promotes pICln-dependent androgen receptor transcription in castration-resistant prostate cancer.
Neoplasms
Protein arginine methyltransferase 5 regulates multiple signaling pathways to promote lung cancer cell proliferation.
Neoplasms
Protein arginine methyltransferase 5 represses tumor suppressor miRNAs that down-regulate CYCLIN D1 and c-MYC expression in aggressive B-cell lymphoma.
Neoplasms
Protein arginine methyltransferase 5 suppresses the transcription of the RB family of tumor suppressors in leukemia and lymphoma cells.
Neoplasms
Protein arginine methyltransferase 5-mediated epigenetic silencing of IRX1 contributes to tumorigenicity and metastasis of gastric cancer.
Neoplasms
Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.
Neoplasms
Protein arginine methyltransferase 5: a potential cancer therapeutic target.
Neoplasms
Protein Arginine Methyltransferase PRMT5 Regulates Fatty Acid Metabolism and Lipid Droplet Biogenesis in White Adipose Tissues.
Neoplasms
Proteomics profiling of arginine methylation defines PRMT5 substrate specificity.
Neoplasms
Rational Design, synthesis and biological evaluation of novel triazole derivatives as potent and selective PRMT5 inhibitors with antitumor activity.
Neoplasms
Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
Neoplasms
RIOK1 kinase activity is required for cell survival irrespective of MTAP status.
Neoplasms
Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma.
Neoplasms
Role of protein arginine methyltransferase 5 in human cancers.
Neoplasms
Selective PRMT5 Inhibitors Suppress Human CD8+ T Cells by Upregulation of p53 and Impairment of the AKT Pathway Similar to the Tumor Metabolite MTA.
Neoplasms
Selective small-chemical inhibitors of protein arginine methyltransferase 5 with anti-lung cancer activity.
Neoplasms
SHARPIN-mediated regulation of protein arginine methyltransferase 5 controls melanoma growth.
Neoplasms
Sirtuin 7-mediated deacetylation of WD repeat domain 77 (WDR77) suppresses cancer cell growth by reducing WDR77/PRMT5 transmethylase complex activity.
Neoplasms
Snail/PRMT5/NuRD complex contributes to DNA hypermethylation in cervical cancer by TET1 inhibition.
Neoplasms
Stochastic modulation evidences a transitory EGF-Ras-ERK MAPK activity induced by PRMT5.
Neoplasms
Sulforaphane inhibits PRMT5 and MEP50 function to suppress the mesothelioma cancer cell phenotype.
Neoplasms
Sulforaphane suppresses PRMT5/MEP50 function in epidermal squamous cell carcinoma leading to reduced tumor formation.
Neoplasms
Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells.
Neoplasms
Targeting methyltransferase PRMT5 retards the carcinogenesis and metastasis of HNSCC via epigenetically inhibiting Twist1 transcription.
Neoplasms
Targeting PRMT5 Activity Inhibits the Malignancy of Hepatocellular Carcinoma by Promoting the Transcription of HNF4?.
Neoplasms
Targeting PRMT5/Akt signalling axis prevents human lung cancer cell growth.
Neoplasms
Targeting protein arginine methyltransferase 5 in disease.
Neoplasms
Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3.
Neoplasms
Targeting protein arginine methyltransferase 5 inhibits human hepatocellular carcinoma growth via the downregulation of beta-catenin.
Neoplasms
Targeting the transcription cycle and RNA processing in cancer treatment.
Neoplasms
The Discovery of Two Novel Classes of 5,5-Bicyclic Nucleoside-Derived PRMT5 Inhibitors for the Treatment of Cancer.
Neoplasms
The E3 ubiquitin ligase CHIP mediates ubiquitination and proteasomal degradation of PRMT5.
Neoplasms
The expression and function of androgen receptor coactivator p44 and protein arginine methyltransferase 5 in the developing testis and testicular tumors.
Neoplasms
The methylation induced by protein arginine methyltransferase 5 promotes tumorigenesis and progression of lung cancer.
Neoplasms
The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond.
Neoplasms
The PRMT5/WDR77 complex regulates alternative splicing through ZNF326 in breast cancer.
Neoplasms
The Proteins Interacting with Prmt5 in Medaka (Oryzias latipes) Identified by Yeast Two-Hybridization.
Neoplasms
The Role of the PRMT5-SND1 Axis in Hepatocellular Carcinoma.
Neoplasms
The Sm protein methyltransferase PRMT5 is not required for primordial germ cell specification in mice.
Neoplasms
The Structure and Function of the PRMT5:MEP50 Complex.
Neoplasms
The uncharacterized protein FAM47E interacts with PRMT5 and regulates its functions.
Neoplasms
Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation.
Neoplasms
Transcriptional activation of PRMT5 by NF-Y is required for cell growth and negatively regulated by the PKC/c-Fos signaling in prostate cancer cells.
Neoplasms
Transcriptional perturbation of protein arginine methyltransferase-5 exhibits MTAP-selective oncosuppression.
Neoplasms
Transition state analogue of MTAP extends lifespan of APCMin/+ mice.
Neoplasms
Tumor necrosis factor (TNF)-? induction of CXCL10 in endothelial cells requires protein arginine methyltransferase 5 (PRMT5)-mediated nuclear factor (NF)-?B p65 methylation.
Neuroblastoma
Protein arginine methyltransferase 5 is a key regulator of the MYCN oncoprotein in neuroblastoma cells.
Nevus, Pigmented
PRMT5 Is Upregulated in Malignant and Metastatic Melanoma and Regulates Expression of MITF and p27(Kip1.)
Obesity
Examining Product Specificity in Protein Arginine Methyltransferase 7 (PRMT7) Using Quantum and Molecular Mechanical Simulations.
Obesity
Prmt7 Deficiency Causes Reduced Skeletal Muscle Oxidative Metabolism and Age-Related Obesity.
Osteoarthritis
PRMT5 inhibition attenuates cartilage degradation by reducing MAPK and NF-?B signaling.
Osteosarcoma
MiRNA-543 promotes osteosarcoma cell proliferation and glycolysis by partially suppressing PRMT9 and stabilizing HIF-1? protein.
Ovarian Neoplasms
Overexpression of PRMT5 Promotes Tumor Cell Growth and Is Associated with Poor Disease Prognosis in Epithelial Ovarian Cancer.
Pancreatic Neoplasms
PRMT1 loss sensitizes cells to PRMT5 inhibition.
Pancreatic Neoplasms
PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis.
Pancreatic Neoplasms
PRMT5 promotes epithelial-mesenchymal transition via EGFR-?-catenin axis in pancreatic cancer cells.
Pancreatic Neoplasms
Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells.
Paralysis
The protein arginine methyltransferase PRMT5 regulates A?-induced toxicity in human cells and Caenorhabditis elegans models of Alzheimer's disease.
Periodontitis
PRMT5 inhibition modulates murine dendritic cells activation by inhibiting the metabolism switch: a new therapeutic target in periodontitis.
Polycythemia Vera
PRMT5 Inhibition Modulates E2F1 Methylation and Gene-Regulatory Networks Leading to Therapeutic Efficacy in JAK2V617F-Mutant MPN.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
PRMT5-mediated H4R3sme2 confers cell differentiation in Pediatric B-cell Precursor Acute Lymphoblastic Leukemia.
Primary Myelofibrosis
PRMT5 Inhibition Modulates E2F1 Methylation and Gene-Regulatory Networks Leading to Therapeutic Efficacy in JAK2V617F-Mutant MPN.
Prostatic Hyperplasia
Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth.
Prostatic Neoplasms
AS1411 Alters the Localization of a Complex Containing Protein Arginine Methyltransferase 5 and Nucleolin.
Prostatic Neoplasms
ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the Androgen Receptor.
Prostatic Neoplasms
MiR-1266 suppresses the growth and metastasis of prostate cancer via targeting PRMT5.
Prostatic Neoplasms
PRMT5 prognostic value in cancer.
Prostatic Neoplasms
PRMT5: a putative oncogene and therapeutic target in prostate cancer.
Prostatic Neoplasms
Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth.
Prostatic Neoplasms
Protein arginine methyltransferase 5 functions in opposite ways in the cytoplasm and nucleus of prostate cancer cells.
Prostatic Neoplasms
Protein arginine methyltransferase 5 promotes pICln-dependent androgen receptor transcription in castration-resistant prostate cancer.
Prostatic Neoplasms
Protein arginine methyltransferase 5 regulates multiple signaling pathways to promote lung cancer cell proliferation.
Prostatic Neoplasms
The E3 ubiquitin ligase CHIP mediates ubiquitination and proteasomal degradation of PRMT5.
Prostatic Neoplasms
Transcriptional activation of PRMT5 by NF-Y is required for cell growth and negatively regulated by the PKC/c-Fos signaling in prostate cancer cells.
Pseudohypoparathyroidism
Further delineation of the phenotype caused by loss of function mutations in PRMT7.
Pulmonary Disease, Chronic Obstructive
PRMT5 promotes inflammation of cigarette smoke extract-induced bronchial epithelial cells by up-regulation of CXCL10.
Reperfusion Injury
Human PRMT5 expression is enhanced during in vitro tubule formation and after in vivo ischemic injury in renal epithelial cells.
Reperfusion Injury
Inhibition of PRMT5 Attenuates Oxidative Stress-Induced Pyroptosis via Activation of the Nrf2/HO-1 Signal Pathway in a Mouse Model of Renal Ischemia-Reperfusion Injury.
Retinoblastoma
EPZ015666, a selective protein arginine methyltransferase 5 (PRMT5) inhibitor with an antitumour effect in retinoblastoma.
Retinoblastoma
PRMT5 Promotes Cyclin E1 and Cell Cycle Progression in CD4 Th1 Cells and Correlates With EAE Severity.
Retinoblastoma
PRMT5-PTEN molecular pathway regulates senescence and self-renewal of primary glioblastoma neurosphere cells.
Retinoblastoma
Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) silencing.
Retinoblastoma
Protein arginine methyltransferase 5 is a potential oncoprotein that upregulates G1 cyclins/cyclin-dependent kinases and the phosphoinositide 3-kinase/AKT signaling cascade.
Sarcoma
Arginine methyltransferase inhibitor-1 inhibits sarcoma viability in vitro and in vivo.
Scoliosis
Regulation of terminal hypertrophic chondrocyte differentiation in Prmt5 mutant mice modeling infantile idiopathic scoliosis.
Seizures
Loss of the arginine methyltranserase PRMT7 causes syndromic intellectual disability with microcephaly and brachydactyly.
Seminoma
The expression and function of androgen receptor coactivator p44 and protein arginine methyltransferase 5 in the developing testis and testicular tumors.
Small Cell Lung Carcinoma
PRMT1 loss sensitizes cells to PRMT5 inhibition.
Squamous Cell Carcinoma of Head and Neck
Expression of protein arginine methyltransferase-5 in oral squamous cell carcinoma and its significance in epithelial-to-mesenchymal transition.
Squamous Cell Carcinoma of Head and Neck
METTL3 Intensifies the Progress of Oral Squamous Cell Carcinoma via Modulating the m6A Amount of PRMT5 and PD-L1.
Squamous Cell Carcinoma of Head and Neck
Nuclear PRMT5, cyclin D1 and IL-6 are associated with poor outcome in oropharyngeal squamous cell carcinoma patients and is inversely associated with p16-status.
Squamous Cell Carcinoma of Head and Neck
Targeting methyltransferase PRMT5 retards the carcinogenesis and metastasis of HNSCC via epigenetically inhibiting Twist1 transcription.
Stomach Neoplasms
Arginine methyltransferase inhibitor 1 inhibits gastric cancer by downregulating eIF4E and targeting PRMT5.
Stomach Neoplasms
LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity.
Stomach Neoplasms
PRMT5-dependent transcriptional repression of c-Myc target genes promotes gastric cancer progression.
Stomach Neoplasms
Protein arginine methyltransferase 5 is associated with malignant phenotype and peritoneal metastasis in gastric cancer.
Stomach Neoplasms
Protein arginine methyltransferase 5-mediated epigenetic silencing of IRX1 contributes to tumorigenicity and metastasis of gastric cancer.
Stomach Neoplasms
Substrate specificity, processivity, and kinetic mechanism of protein arginine methyltransferase 5.
Teratoma
PRMT5 is Required for Human Embryonic Stem Cell Proliferation But Not Pluripotency.
Testicular Neoplasms
The expression and function of androgen receptor coactivator p44 and protein arginine methyltransferase 5 in the developing testis and testicular tumors.
Triple Negative Breast Neoplasms
Elevated expression of protein arginine methyltransferase 5 predicts the poor prognosis of breast cancer.
Triple Negative Breast Neoplasms
Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.
type ii protein arginine methyltransferase deficiency
Coordinated Splicing of Regulatory Detained Introns within Oncogenic Transcripts Creates an Exploitable Vulnerability in Malignant Glioma.
type ii protein arginine methyltransferase deficiency
Methylation determines the extracellular calcium sensitivity of the leak channel NALCN in hippocampal dentate granule cells.
type ii protein arginine methyltransferase deficiency
PRMT5 is required for cell-cycle progression and p53 tumor suppressor function.
type ii protein arginine methyltransferase deficiency
PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington's disease (HD).
type ii protein arginine methyltransferase deficiency
PRMT7 deficiency causes dysregulation of the HCN channels in the CA1 pyramidal cells and impairment of social behaviors.
type ii protein arginine methyltransferase deficiency
Prmt7 Deficiency Causes Reduced Skeletal Muscle Oxidative Metabolism and Age-Related Obesity.
type ii protein arginine methyltransferase deficiency
PRMT7 deficiency enhances adipogenesis through modulation of C/EBP-?.
type ii protein arginine methyltransferase deficiency
Structure and Function of Protein Arginine Methyltransferase PRMT7.
Urinary Bladder Neoplasms
High PRMT5 expression is associated with poor overall survival and tumor progression in bladder cancer.
Urinary Bladder Neoplasms
Protein arginine methyltransferase 5 promotes bladder cancer growth through inhibiting NF-kB dependent apoptosis.
Uterine Cervical Neoplasms
Arginine methyltransferase inhibitor 1 exhibits antitumor effects against cervical cancer in vitro and in vivo.
Uterine Cervical Neoplasms
Epigallocatechin gallate inhibits HeLa cells by modulation of epigenetics and signaling pathways.
Uterine Cervical Neoplasms
PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PD-L1 expression.
Uterine Cervical Neoplasms
Snail/PRMT5/NuRD complex contributes to DNA hypermethylation in cervical cancer by TET1 inhibition.
Viremia
Zebrafish prmt7 negatively regulates antiviral responses by suppressing the retinoic acid-inducible gene-I-like receptor signaling.
Virus Diseases
Arginine monomethylation by PRMT7 controls MAVS-mediated antiviral innate immunity.
Virus Diseases
Nuclear cGAS Functions Non-canonically to Enhance Antiviral Immunity via Recruiting Methyltransferase Prmt5.
Virus Diseases
PRMT5 Is Required for Bovine Leukemia Virus Infection In Vivo and Regulates BLV Gene Expression, Syncytium Formation, and Glycosylation In Vitro.
Wilms Tumor
Transcriptomic Analyses of MYCN-Regulated Genes in Anaplastic Wilms' Tumour Cell Lines Reveals Oncogenic Pathways and Potential Therapeutic Vulnerabilities.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.0000079
(1R,2S,3R,5R)-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-[(E)-2-(quinolin-7-yl)ethenyl]cyclopentane-1,2-diol
Homo sapiens
pH and temperature not specified in the publication
0.000002
(1R,2S,3R,5R)-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-[(S)-(3,4-difluorophenyl)(hydroxy)methyl]cyclopentane-1,2-diol
Homo sapiens
pH and temperature not specified in the publication
0.000026
(1R,2S,3R,5R)-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-[[(quinolin-7-yl)oxy]methyl]cyclopentane-1,2-diol
Homo sapiens
pH and temperature not specified in the publication
0.00000079
(1R,2S,3R,5S)-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(2-[2-[(cyclopropylmethyl)amino]quinolin-7-yl]ethyl)cyclopentane-1,2-diol
Homo sapiens
pH and temperature not specified in the publication
0.0000002
(1R,2S,3R,5S)-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-[2-(2,3-dimethylimidazo[1,2-a]pyridin-7-yl)ethyl]cyclopentane-1,2-diol
Homo sapiens
pH and temperature not specified in the publication
0.00000025
(1R,2S,3R,5S)-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-[2-(2-aminoquinolin-7-yl)ethyl]cyclopentane-1,2-diol
Homo sapiens
pH and temperature not specified in the publication
0.000008
(1R,2S,3R,5S)-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-[2-(3-methylimidazo[1,2-a]pyridin-7-yl)ethyl]cyclopentane-1,2-diol
Homo sapiens
pH and temperature not specified in the publication
0.0000016
(1R,2S,3R,5S)-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-[2-(6-chloro-3-methylimidazo[1,2-a]pyridin-7-yl)ethyl]cyclopentane-1,2-diol
Homo sapiens
pH and temperature not specified in the publication
0.00000032
(1R,2S,3R,5S)-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-[2-(6-fluoro-3-methylimidazo[1,2-a]pyridin-7-yl)ethyl]cyclopentane-1,2-diol
Homo sapiens
pH and temperature not specified in the publication
0.0000063
(1R,2S,3R,5S)-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-[2-(quinolin-7-yl)ethyl]cyclopentane-1,2-diol
Homo sapiens
pH and temperature not specified in the publication
0.000002
(1S,2R,3R,5R)-3-[(R)-hydroxy(1,2,3,4-tetrahydroisoquinolin-8-yl)methyl]-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol
Homo sapiens
pH and temperature not specified in the publication
0.00000013
(1S,2R,3S,5R)-3-[2-(2-amino-3-bromoquinolin-7-yl)ethyl]-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol
Homo sapiens
pH and temperature not specified in the publication
0.000000501
(1S,2R,3S,5R)-3-[2-(6-aminopyridin-3-yl)ethyl]-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol
Homo sapiens
pH and temperature not specified in the publication
0.0000004
(1S,2R,3S,5R)-3-[4-(6-aminopyridin-2-yl)butyl]-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol
Homo sapiens
pH and temperature not specified in the publication
0.000026
(1S,2S,3R,5S)-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-[(4-chloro-3-fluorophenyl)sulfanyl]cyclopentane-1,2-diol
Homo sapiens
pH and temperature not specified in the publication
0.000126
(1S,2S,3R,5S)-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-[(quinolin-7-yl)methoxy]cyclopentane-1,2-diol
Homo sapiens
pH and temperature not specified in the publication
0.000001
(1S,2S,3R,5S)-3-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-[(1,2,3,4-tetrahydroisoquinolin-8-yl)oxy]cyclopentane-1,2-diol
Homo sapiens
pH and temperature not specified in the publication
0.000002
(1S,2S,3R,5S)-3-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-[[6-(trifluoromethyl)-1,2,3,4-tetrahydroisoquinolin-8-yl]oxy]cyclopentane-1,2-diol
Homo sapiens
pH and temperature not specified in the publication
0.000001
(1S,2S,3S,5R)-3-[(5-fluoro-6-methoxy-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy]-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol
Homo sapiens
pH and temperature not specified in the publication
0.000001
(1S,2S,3S,5R)-3-[(6-bromo-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy]-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol
Homo sapiens
pH and temperature not specified in the publication
0.000001
(1S,2S,3S,5R)-3-[[6-(difluoromethoxy)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl]oxy]-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol
Homo sapiens
pH and temperature not specified in the publication
0.000001
(1S,2S,3S,5R)-3-[[6-(difluoromethyl)-1,2,3,4-tetrahydroisoquinolin-8-yl]oxy]-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol
Homo sapiens
pH and temperature not specified in the publication
0.000001
(1S,2S,3S,5R)-3-[[6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl]oxy]-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol
Homo sapiens
pH and temperature not specified in the publication
0.000001
(1S,2S,3S,5R)-3-[[6-(difluoromethyl)-5-fluoro-4-methyl-1,2,3,4-tetrahydroisoquinolin-8-yl]oxy]-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol
Homo sapiens
pH and temperature not specified in the publication
0.000001
(2R,3S,4R,5R)-2-[(S)-hydroxy(1,2,3,4-tetrahydroisoquinolin-8-yl)methyl]-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)oxolane-3,4-diol
Homo sapiens
pH and temperature not specified in the publication
0.0000006
(4Z)-7-[(5R)-5-amino-5-(4-chlorophenyl)-5-deoxy-beta-D-ribofuranosyl]-4-hydrazinylidene-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidine
Homo sapiens
pH and temperature not specified in the publication
0.000003
(5R)-5'-C-(3,4-difluorophenyl)adenosine
Homo sapiens
pH and temperature not specified in the publication
0.000517
1-(6-bromo-9-ethyl-9H-carbazol-3-yl)-N-[(2-methoxyphenyl)methyl]methanamine
Homo sapiens
pH and temperature not specified in the publication
0.000116
1-[(5R)-5-C-(4-chlorophenyl)-beta-D-ribofuranosyl]-3-ethynyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
Homo sapiens
pH and temperature not specified in the publication
0.0028
2-([[2-(benzyloxy)-1,4-dihydronaphthalen-1-yl]methyl]amino)-1-phenylethan-1-ol
Homo sapiens
pH and temperature not specified in the publication
0.04587
3-(3,4-dihydroisoquinolin-2(1H)-yl)-N-(3-fluorophenyl)propanamide
Homo sapiens
pH and temperature not specified in the publication
0.06295
3-(3,4-dihydroisoquinolin-2(1H)-yl)-N-[3-(trifluoromethoxy)phenyl]propanamide
Homo sapiens
pH and temperature not specified in the publication
0.06987
3-(3,4-dihydroisoquinolin-2(1H)-yl)-N-[4-(trifluoromethyl)pyrimidin-2-yl]propanamide
Homo sapiens
pH and temperature not specified in the publication
0.000009
7-[(5R)-5-amino-5-deoxy-5-(3,4-difluorophenyl)-beta-D-ribofuranosyl]-4-methyl-7H-pyrrolo[2,3-d]pyrimidine
Homo sapiens
pH and temperature not specified in the publication
0.000003
7-[(5R)-5-C-(3,4-difluorophenyl)-beta-D-ribofuranosyl]-4-methyl-7H-pyrrolo[2,3-d]pyrimidine
Homo sapiens
pH and temperature not specified in the publication
0.000002
7-[(5R)-5-C-(3,4-difluorophenyl)-beta-D-ribofuranosyl]-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-4-amine
Homo sapiens
pH and temperature not specified in the publication
0.000001
7-[(5R)-5-C-(3,4-difluorophenyl)-beta-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
Homo sapiens
pH and temperature not specified in the publication
0.00000002
7-[(5R)-5-C-(4-chloro-3-fluorophenyl)-beta-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
Homo sapiens
pH and temperature not specified in the publication
0.000017
7-[(5R)-5-C-(4-chlorophenyl)-beta-D-ribofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine
Homo sapiens
pH and temperature not specified in the publication
0.0000043
7-[(5R)-5-C-(4-chlorophenyl)-beta-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
Homo sapiens
pH and temperature not specified in the publication
0.0000095 - 0.000026
7-[(5R)-5-C-phenyl-beta-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
0.0000158
7-[5-O-(quinolin-7-yl)-beta-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
Homo sapiens
pH and temperature not specified in the publication
0.000001
8-[[(1S,2S,3S,4R)-2,3-dihydroxy-4-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentyl]oxy]-1,2,3,4-tetrahydroisoquinoline-6-carbonitrile
Homo sapiens
pH and temperature not specified in the publication
0.000035
dehydrosinefungin
Homo sapiens
pH and temperature not specified in the publication
0.06
methyl 2-[2-(3,4-dihydroisoquinolin-2(1H)-yl)acetamido]benzoate
Homo sapiens
pH and temperature not specified in the publication
0.00033
methyl 2-[2-[(6-methoxy-1H-benzimidazol-2-yl)sulfanyl]acetamido]benzoate
Homo sapiens
pH and temperature not specified in the publication
0.03162
methyl 2-[3-(3,4-dihydroisoquinolin-2(1H)-yl)propanamido]benzoate
Homo sapiens
pH and temperature not specified in the publication
0.08789
methyl 2-[4-(3,4-dihydroisoquinolin-2(1H)-yl)butanamido]benzoate
Homo sapiens
pH and temperature not specified in the publication
0.07254
N'-[3-(3,4-dihydroisoquinolin-2(1H)-yl)propanoyl]benzohydrazide
Homo sapiens
pH and temperature not specified in the publication
0.02555
N-(2-cyanophenyl)-3-(3,4-dihydroisoquinolin-2(1H)-yl)propanamide
Homo sapiens
pH and temperature not specified in the publication
0.05195
N-(3-acetylphenyl)-3-(3,4-dihydroisoquinolin-2(1H)-yl)propanamide
Homo sapiens
pH and temperature not specified in the publication
0.00271
N-(3-bromo-2-cyanophenyl)-3-(3,4-dihydroisoquinolin-2(1H)-yl)propanamide
Homo sapiens
pH and temperature not specified in the publication
0.01812
N-(3-bromophenyl)-3-(3,4-dihydroisoquinolin-2(1H)-yl)propanamide
Homo sapiens
pH and temperature not specified in the publication
0.04213
N-(3-chlorophenyl)-3-(3,4-dihydroisoquinolin-2(1H)-yl)propanamide
Homo sapiens
pH and temperature not specified in the publication
0.000047
N-[(2S)-3-(3,4-dihydro-2(1H)-isoquinolinyl)-2-hydroxypropyl]-6-(3-oxetanylamino)-4-pyrimidinecarboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000022
N-[(2S)-3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl]-6-[(oxetan-3-yl)amino]pyrimidine-4-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.00056
S-adenosyl-L-homocysteine
Homo sapiens
pH and temperature not specified in the publication
0.0000095
7-[(5R)-5-C-phenyl-beta-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
Homo sapiens
pH and temperature not specified in the publication
0.000026
7-[(5R)-5-C-phenyl-beta-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
Homo sapiens
pH and temperature not specified in the publication
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.